フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
ST. LOUIS, June 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) (the "Company") today announced that it received a letter...
ST. LOUIS and BUDAPEST, Hungary, June 18 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that it has entered...
KV acknowledges validity of Purdue patents; Receives limited license rights to all strengths of oxycodone controlled-release tablets ST. LOUIS...
Entity not core to Company's finished dose pharmaceutical business ST. LOUIS, June 3 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:...
Decree outlines path forward to resume manufacturing at KV facilities ST. LOUIS, March 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company...
Layoffs result from recent challenges, effort to reduce costs ST. LOUIS, Feb. 9 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company...
ST. LOUIS, Feb. 3 /PRNewswire/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical Company (NYSE:KVa/KVb), is issuing a voluntary...
Previously Issued Recall to Wholesale Level on Certain Products Expanded to Retail Level ST. LOUIS, Feb. 3 /PRNewswire/ -- ETHEX Corporation, a...
Sets New Standard for Prescription Prenatal Vitamins ST. LOUIS, Dec. 17 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb...
KV Pharmaceutical Company (NYSE: KV-A) will hold an analyst conference call at 4 p.m. EST (3 p.m. CST) today to introduce interim...
KV Pharmaceutical Company (NYSE: KV-A) announced today that the Board of Directors has terminated, for cause, the employment...
Discusses Factors Affecting Previously Disclosed Preliminary Results ST. LOUIS, Nov. 17 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company...
ST. LOUIS, Nov. 13 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa; KVb) announced that it has filed with the U.S. Securities and...
ST. LOUIS, Nov. 10 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) announced today that due to the ongoing Audit Committee...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約